Clinical trial
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
NCT03646721 is registered in ClinicalTrials.gov with Dong-A ST Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
- Lead sponsor
- Dong-A ST Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 29, 2018
- Completion date
- May 7, 2020
- Enrollment
- 108 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.